Dendritic cells stimulate cancer-cell growth

Since their discovery at Rockefeller University some 30 years ago, dendritic cells have been recognized as key players on the immune-system team, presenting antigens to other immune cells to help them respond to novel insults. Now, Rockefeller scientists have shown that dendritic cells also have other, non-immune actions, and may in fact directly modify the biology of some types of cancer cells.

The results, reported recently in the Journal of Experimental Medicine, begin to clarify how the complex microenvironment of tumors promotes or inhibits their growth, which could be useful for devising novel cancer treatments.

“Tumors reside in a very complex environment that includes many, many kinds of cells,” says Madhav Dhodapkar, head of Rockefeller’s Laboratory of Tumor Immunology and Immunotherapy. “Cancer is not a disease just of the cancer cell, but of that cell in the context of everything else around it.” Dendritic cells, in particular, are abundant in myeloma and other tumors. They are attracted by chemical signals secreted by tumor cells, and were suspected of modulating the immune system so that it tolerates tumors instead of attacking them.

Dhodapkar’s research focuses on multiple myeloma, the unchecked proliferation of plasma cells in bone marrow. These immune cells are the final developmental stage of B cells, and are tuned to respond to specific antigens. The team, including Anjli Kukreja, a postdoc in the lab, used specialized culture systems to explore how individual components of the microenvironment influence cancer development. Ordinarily, only about one tumor cell out of a hundred forms a colony in these cultures, but when the scientists introduced progressively more dendritic cells, the number of colonies progressively increased, ultimately multiplying by a factor of more than 10. They also saw increased growth in lymphoma and breast cancer cultures, but not in glioma, a brain cancer. Previous research had found that macrophages, a cousin of dendritic cells, directly affect tumor-cell growth, but the effect had never been observed with dendritic cells.

The dendritic cells also caused some tumor cells to go “backward” in development, resuming production of a chemical marker that had been shut off as they progressed from B cells to plasma cells. “These data suggest that the differentiation state of myeloma cells may be plastic, and capable of change in response to the microenvironment,” Dhodapkar explains. “This plasticity could be important in understanding how tumors develop.”

The researchers also identified two chemical signaling pathways by which the dendritic cells influence tumor cells, suggesting that complementary molecules on the surfaces of the two types of cells act only when the cells are in direct contact.

The supporting role of dendritic cells in tumors is also providing new insights into treatment. In a followup study in the British Journal of Haematology, Dhodapkar's team reports that a well-known myeloma drug, bortezomib, disrupts the interaction between tumor and dendritic cells in culture, and also kills the problematic dendritic cells. “In myeloma we are learning that both tumors and their environment need to be targeted for effective therapies,” he says.

Citation: Journal of Experimental Medicine 203(8): 1859-1865 (August 2006)
British Journal of Haematology Online: October 24, 2006

Source: Rockefeller University

Related stories:

New nano device detects immune system cell signaling
Scientists have detected previously unnoticed chemical signals that individual cells in the immune system use to communicate with each other over short distances.
Carnegie Mellon MRI technology that non-invasively locates, quantifies specific cells in the body
Magnetic resonance imaging (MRI) isn't just for capturing detailed images of the body's anatomy. Thanks to novel imaging reagents and technology developed by Carnegie Mellon University scientist Eric Ahrens, MRI can be used to visualize — with "exquisite" specificity — cell populations of interest in the living body. The ability to non-invasively locate and track cells, such as immune cells, will greatly aid the study and treatment of cancer, inflammation, and autoimmune diseases, as well as provide a tool for advancing clinical translation of the emerging field of cellular regenerative medicine, by tracking stem cells for example.
Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes
Researchers conducting a clinical trial of a dendritic cell vaccine designed to fight malignant brain tumors called glioblastoma multiforme (GBM) have found a correlation between the "intensity" of a patient's immune response and clinical outcome, according to an article in the July 15 issue of the journal Cancer Research.
Cancer drug shows promise against graft vs. host disease
A new University of Michigan study in mice suggests that a drug recently approved to fight cancer tumors is also able to reduce the effects of graft-versus-host disease, a common and sometimes fatal complication for people who have had bone marrow transplants.
Understanding the migration of cancer cells
Activity of regulatory proteins for the growth of filopodia and lamelopodia clarified
Lamellipodia are veil-shaped protrusions of the plasma membrane, that can turn into upward-curled ruffles if they fail to adhere to the substrate. A dendritic meshwork of short and highly branched actin filaments might constitute their main structural component. The other type of protrusion, the filopodia, are finger-like and consist of parallel, long and unbranched actin filaments. Interestingly, fast-crawling cells mainly form lamellipodia/ruffles while poorly migrating or non-motile cells often show the coexistence of both lamellipodial and filopodial protrusions. These observations suggest that the lamellipodia-to-filopodia selection might regulate cell migration. Moreover, the pivotal contribution of lamellipodial and filopodial protrusions to important developmental and homeostatic processes certainly requires tight regulatory mechanisms.
UF scientists to work with German firm in prostate cancer treatment research
University of Florida department of urology officials signed an agreement Tuesday to collaborate with the German biopharmaceutical company CureVac to test an experimental therapy for advanced prostate cancer patients who no longer respond to traditional treatment.
Immune system pathway identified to fight allergens, asthma
For the first time, researchers from the University of Pittsburgh School of Medicine have identified genetic components of dendritic cells that are key to asthma and allergy-related immune response malfunction. Targeting these elements could result in more effective drugs to treat allergic disorders and asthma, according to a study reported in the May edition of the journal Nature Medicine.
Researchers uncover new genetic links to psoriasis
In the first comprehensive study of the genetic basis of psoriasis, researchers at Washington University School of Medicine in St. Louis have discovered seven new sites of common DNA variation that increase the risk of the troublesome skin condition. They also found that variations in one genetic region link psoriasis and a related joint disorder, psoriatic arthritis, to four autoimmune diseases: type 1 diabetes, Grave's disease, celiac disease and rheumatoid arthritis. The study's results appear April 4 in the open-access journal PLoS Genetics.

News discussion:

Medicine & Health news